cohen lab page
Dr. Jeffrey Huang
PhD, Rosalind Franklin University/Chicago Medical School
I received my bachelor degree in molecular and cell biology (neurobiology emphasis) from the University of California, Berkeley. Following my undergraduate studies, I worked as a lab technician in academia-Hepatitis C virology lab at the University of Southern California-and in industry. My interest in neurodegenerative disorders and molecular biology/virology led me to pursue a PhD in neuroscience at Rosalind Franklin University of Medicine & Science. My doctoral research focused on the role of human neprilysin 2 (NEP2) in Alzheimer’s disease. My work characterized the in vitro β-amyloid degrading properties of NEP2, alterations in NEP2 mRNA and enzymatic activity in Alzheimer’s brain tissue, and the therapeutic potential of lentiviral NEP2 gene therapy. After receiving my doctorate, I joined the Cohen lab to examine the role of ADP-ribosyltransferases (ARTs or PARPs) on learning and memory and in the pathogenesis of neurodegenerative disorders. I am especially interested in applying my background in molecular biology and behavioral neuroscience to investigating the effects of ART/PARP-specific inhibitors. Outside the lab, my personal interests include archaeology, the history and statistics of baseball, and investing in the stock market.
Dr. Haihong Jin
PhD, University of Connecticut
I received my PhD from the University of Connecticut. Following my doctoral studies, I worked as a Senior Development Chemist in the Crop Protection Process Research and Development Department at Chemtura Corporation. At Chemtura, I developed a manufacturing process for the miticide Bifenazate. I then decided to transition to a career in Medical Chemistry and took a position as a Senior Medicinal Scientist at Lexicon Pharmaceuticals. During my time at Lexicon, I invented a new method of constructing 2-amino methyl thiazole-5-carboxamides compounds for kinase inhibitor libraries. I also led several projects that resulted in the advancement of three candidates into clinical trials: LX1031, which showed efficacy in Phase IIa for the treatment of irritable bowel syndrome (IBS); LX 1032, which is in Phase II for carcinoid syndrome; and LX1033, which is in Phase I for IBS. After my tenure in industry, I joined the Cohen lab where I am applying my expertise in organic and medicinal chemistry to develop small molecule probes of ADP-ribosyltransferases. I am also interested in identifying small molecule inhibitors as potential therapeutics for human diseases, including neurodegeneration and cancer.